一个优化的Nurr1激动剂在帕金森病模型中提供了疾病修饰效应
Woori Kim1,2, Mohit Tripathi3, Chunhyung Kim1,2
1Department of Psychiatry, McLean Hospital, Harvard Medical School, Belmont, MA, 02478, USA.
Nature communications
|July 18, 2023
概括
研究人员开发了一种新型化合物,4A7C-301,针对Nurr1蛋白来保护多巴胺神经元. 这种帕金森病候选药物在临床前模型中显示出前景,改善了运动和非运动症状.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
背景情况:
- Nurr1对于多巴胺神经元的发育和维护至关重要.
- Nurr1是帕金森病 (PD) 的一个有前途的治疗点.
- 之前的工作已经确定了4-amino-7-chloroquinoline (4A7C) 衍生物作为Nurr1激动剂.
研究的目的:
- 系统地探索4A7C化学支架,寻找新的Nurr1激动剂.
- 识别和优化具有神经保护性质的穿透大脑的Nurr1激动剂.
- 在PD的临床前模型中评估优化化合物的治疗潜力.
主要方法:
- 合成和描述超过570种4A7C衍生物.
- 测试用于增强Nurr1转录活性的化合物.
- 在体外神经保护测定.
- 在MPTP诱导和α-synuclein过度表达的PD小鼠模型中的体内测试.
主要成果:
- 鉴定4A7C-301,一个强大的,穿透大脑的Nurr1激动剂.
- 4A7C-301在体外显示出强大的神经保护作用.
- 4A7C-301 改善了PD小鼠模型中的运动和嗅觉缺陷,而没有诱导动力障碍.
- 在α-synuclein模型中,4A7C-301改善了神经病理异常.
结论:
- 优化的4A7C衍生物4A7C-301在临床前PD模型中表现出显著的疾病修饰特性.
- 4A7C-301显示神经保护作用并改善运动和非运动症状.
- 这些发现支持对4A7C-301或类似化合物的临床评估,用于治疗帕金森病.
相关概念视频
01:24Parkinson's Disease: Treatment
301
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
301
01:15Parkinson's Disease: Overview
601
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
601
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
343
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
343
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
793
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
793
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
716
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
716